NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Synchron

Synchron

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.synchron.com

Last Round

Series D

Nov 6, 2025

Total Funding Raised

$325M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Synchron is a neurotechnology company that develops an implantable brain-computer interface to interpret brain signals for treating conditions like paralysis, epilepsy, and movement disorders through a minimally invasive device.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials, Medical AI, Health IoT

Business Model

B2B2C

Customer Profile

Hardware Sales, Government Contracts, Hardware + Subscription, Services & Consulting

AI Layer

Infrastructure

Keywords

brain-computer interfaceBCIendovascular BCIStentrodebrain implantminimally invasive BCIthought controlneurotechnologyassistive technologyneural signal decodingparalysis treatmentcognitive AIendovascular procedurebrainOSbreakthrough device designation

Price History

Caplight MarketPrice™ estimate for Synchron, published with a 90-day delay.

Delayed data

Caplight MarketPrice™

$44.48

per share, as of March 2026

+20.0%

6-month change

The most recent months of MarketPrice™ are available to Caplight clients.

Caplight MarketPrice™ is an estimate of private secondary market pricing, shown here on a delayed basis for illustrative purposes only. It may be incomplete, is subject to change, and may not be relied upon for any purpose or considered investment advice.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Synchron Comparables

Compare Synchron with similar companies based on industry and business-model similarity.

Synchron comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Paradromics
89%
Precision Neuroscience
86%
Neuralink
84%

Synchron Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DNov 6, 2025
Series CDec 15, 2022
Series BJun 3, 2021
Series AApr 4, 2017

Key People

Founding team and executive leadership

Thomas Oxley

CEO

Executive Team

Synchron Investors

Notable investors and investment history

Synchron investors
InvestorRounds
Forepont Capital PartnersSeries B, Series C
Greenoaks Capital PartnersSeries C
Khosla VenturesSeries C, Series D, Series B
U.S. Department of DefenseSeries A
Bezos ExpeditionsSeries C, Series D
re.Mind CapitalSeries B
T.Rx CapitalSeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 24, 2026

    Named to Fast Company's Most Innovative Companies list.

  • Mar 24, 2026

    Named to Fast Company's Most Innovative Companies list for 2026.

Synchron Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Synchron Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Synchron's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range131
Year Founded2016
Last FundingNov 6, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.